8-K: Accendra Health Completes P&HS Sale, Reports Q4/FY25 Results

Accendra Health, Inc. announced its fourth quarter and full-year 2025 financial results, highlighted by the completion of its Products & Healthcare Services business sale and a strategic pivot towards its continuing operations.

Summary

• Completed the sale of the Products & Healthcare Services (P&HS) business on December 31, 2025, for an estimated final purchase price of $356 million.
• Full-year 2025 net revenue from continuing operations was $2.76 billion, representing 3% growth compared to the prior year.
• Full-year 2025 operating cash flow from continuing operations was $154 million.
• Reported a GAAP net loss of $(1,100.6) million for the full year 2025, significantly higher than $(362.7) million in 2024, primarily due to a $(998.0) million loss from discontinued operations.
• Adjusted EBITDA from continuing operations for full-year 2025 was $374.8 million, up from $370.5 million in 2024.
• Provided 2026 financial guidance for continuing operations: revenue ranging between $2.55 billion and $2.65 billion, adjusted EBITDA between $335 million and $355 million, and free cash flow between $90 million and $110 million.
• Cash and cash equivalents increased significantly to $281.99 million at December 31, 2025, from $27.57 million at December 31, 2024.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While the strategic divestiture and improved cash position are positive, the significant GAAP net loss and lower 2026 guidance for key operational metrics indicate ongoing challenges and a period of transition.

Positives

• Successful completion of the Products & Healthcare Services (P&HS) business sale on December 31, 2025, streamlining operations and generating $342.35 million in proceeds by year-end.
• Full-year 2025 net revenue from continuing operations grew 3% to $2.76 billion, indicating organic growth in the core business.
• Full-year 2025 operating cash flow from continuing operations was strong at $154 million, demonstrating operational efficiency.
• Adjusted EBITDA from continuing operations increased to $374.8 million in 2025 from $370.5 million in 2024, showing consistent profitability in the core segment.
• Significant increase in cash and cash equivalents to $281.99 million at year-end 2025, up from $27.57 million in 2024, enhancing liquidity.
• GAAP loss from continuing operations improved in Q4 2025 to $(9.4) million from $(331.9) million in Q4 2024, reflecting better performance in the core business.
• Management expects to be a 'leaner, more nimble company' focused on sustainable growth and long-term value creation post-divestiture.

Negatives

• Reported a substantial GAAP net loss of $(1,100.6) million for the full year 2025, significantly worse than $(362.7) million in 2024, primarily driven by a $(998.0) million loss from discontinued operations.
• Adjusted net income from continuing operations decreased in Q4 2025 to $16.7 million from $25.0 million in Q4 2024.
• Adjusted EBITDA from continuing operations decreased in Q4 2025 to $90.0 million from $102.5 million in Q4 2024.
• Free cash flow from continuing operations decreased in Q4 2025 to $18.3 million from $30.1 million in Q4 2024.
• The 2026 financial outlook projects a decrease in revenue (midpoint $2.6 billion vs. $2.76 billion in 2025) and Adjusted EBITDA (midpoint $345 million vs. $374.8 million in 2025) for continuing operations.
• Total equity shifted to a deficit of $(460.98) million at December 31, 2025, from a positive equity of $586.36 million at December 31, 2024.

Risks

• Forward-looking statements involve known and unknown risks and uncertainties that may cause actual results in future periods to differ materially from those projected or contemplated.
• Future prospects and performance, including financial performance, 2026 financial results, and business performance following the completion of the P&HS business sale, are subject to risks.
• Cost saving initiatives, future indebtedness and growth, and industry trends may not materialize as expected.
• The company's ability to address macro and market conditions, consumer demand, supply chain stability, and interest rates could impact financial results.
• Restructuring and acquisition charges, which are unpredictable, could have a significant impact on GAAP results.

Future Outlook

Accendra Health projects 2026 revenue from continuing operations to be between $2.55 billion and $2.65 billion, adjusted EBITDA between $335 million and $355 million, and free cash flow between $90 million and $110 million. This outlook reflects the company's strategic repositioning post-divestiture, focusing on cost controls, improved cash flow generation, and balance sheet optimization, aiming to become a leaner, more nimble company driving sustainable growth.

Management Comments

• "We ended the fourth quarter with the completion of the sale of the Products & Healthcare Services (P&HS) business on December 31, 2025, and we are extremely excited to embark on the next chapter of our business as Accendra Health."
• "The next several months will be a period of transition as we work towards completing the separation from Owens & Minor, thereby unlocking the strength of Accendra Health."
• "As we look ahead, we are entering 2026 as a leaner, more nimble company that is well positioned to drive sustainable growth and long-term value creation."
• "We will be focused on improving the strength of our financial position through cost controls, improved cash flow generation, and balance sheet optimization."
• "In the years ahead, we look forward to showcasing Accendras continuation of higher quality of earnings, low working capital requirements, and more stable and consistent cash flow generation leading to greater value for all stakeholders."

Industry Context

StockSavvy.ai notes that Accendra Health's divestiture of its P&HS business and focus on its Patient Direct segment aligns with a broader trend in healthcare towards specialized, home-based care solutions, particularly for chronic and complex conditions. This strategic shift aims to capitalize on the growing demand for efficient, patient-centric care outside traditional hospital settings, potentially enhancing profitability and reducing capital intensity compared to diversified healthcare product distribution.

Legal Proceedings

• Litigation and related charges, including settlement costs, were $2.418 million for the year ended December 31, 2025, and $17.119 million for the year ended December 31, 2024, indicating ongoing legal matters.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through strategic repositioning, but short-term uncertainty due to lower 2026 guidance and a significant GAAP net loss. The shift to an equity deficit is a notable concern.
• Employees: Implied strategic realignments and cost controls may lead to further organizational changes as the company becomes 'leaner and more nimble'.
• Customers: Continued focus on home-based care through Apria and Byram brands aims to improve health outcomes and quality of life for people with chronic conditions.
• Creditors: Debt reduction in the quarter and a focus on balance sheet optimization could improve the credit profile over time, but the current portion of long-term debt increased significantly.

Next Steps

• Complete the separation from Owens & Minor.
• Focus on cost controls, improved cash flow generation, and balance sheet optimization.
• File the Annual Report on Form 10-K for the year ended December 31, 2025, around February 20, 2026.
• Host an investor conference call on February 19, 2026, at 5:00 p.m. E.T.

Key Dates

Recommendation

The strategic divestiture of the P&HS business and the focus on core continuing operations, coupled with strong cash flow generation and debt reduction, present a clearer, more focused business model. However, the substantial GAAP net loss for 2025 and the lower 2026 guidance for key operational metrics suggest a period of transition and potential headwinds. Investors should hold to observe the execution of the new strategy and the realization of anticipated efficiencies before making further commitments.

Keywords

Accendra Health, ACH, financial results, Q4 2025, full year 2025, P&HS sale, Products & Healthcare Services, continuing operations, Patient Direct, healthcare services, financial outlook, 2026 guidance, Adjusted EBITDA, free cash flow, revenue, corporate restructuring, home-based care, Apria, Byram